Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
AffiliationChristie Hospital, Manchester
MetadataShow full item record
AbstractPretreatment serum beta 2m levels were estimated in 65 patients with multiple myeloma. After correction for changes in renal function, the level of beta 2m attributable to multiple myeloma (beta 2m-m) no longer correlated with the serum creatinine, but showed a strong correlation with the total body myeloma cell mass (P = 0.002). There was an inverse correlation between beta 2m-m and the Karnofsky performance status of patients at presentation (P = 0.001). Patients with a pretreatment beta 2m-m level of less than the median value of 2.94 mg/l survived significantly longer than those with a raised level (P = 0.0008).
CitationPrognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma. 1983, 19 (10):1361-4 Eur J Cancer Clin Oncol
JournalEuropean Journal of Cancer & Clinical Oncology
- Pretreatment serum beta 2-microglobulin in multiple myeloma.
- Authors: Brenning G, Simonsson B, Källander C, Ahre A
- Issue date: 1986 Jan
- Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma.
- Authors: Brenning G, Wibell L, Bergström R
- Issue date: 1985 Oct
- [Prognostic importance of beta-2-microglobulin in multiple myeloma].
- Authors: Avilés A, Zepeda G, Guzmán R, Talavera A, García EL, Díaz-Maqueo JC
- Issue date: 1992 Apr-Jun
- Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
- Authors: Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamäki A, Tienhaara A, Laakso M, Lahtinen R
- Issue date: 1995 Feb 1
- Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.
- Authors: Cuzick J, De Stavola BL, Cooper EH, Chapman C, MacLennan IC
- Issue date: 1990 Aug